Correction: Up-regulation of p16 by miR-877-3p inhibits proliferation of bladder cancer (Oncotarget (2016) 7 (51773-51783) DOI: 10.18632/oncotarget.10575);Up-regulation of p16 by miR-877-3p inhibits proliferation of bladder cancer

Oncotarget

Volumn 7, Issue 32, 2016, Pages 51773-51783

  Li, Shiqi ^a   Zhu, Yi ^a   Liang, Zhen ^a   Wang, Xiao ^a   Meng, Shuai ^a   Xu, Xin ^a   Xu, Xianglai ^a   Wu, Jian ^a   Ji, Alin ^a   Hu, Zhenghui ^a   Lin, Yiwei ^a   Chen, Hong ^a   Mao, Yeqing ^a   Wang, Wei ^a   Zheng, Xiangyi ^a   Liu, Ben ^a   Xie, Liping ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Bladder cancer; MicroRNA 877 3p; P16; RNA activation

Indexed keywords

MICRORNA; MICRORNA 877 3P; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MIRN877 MICRORNA, HUMAN; P16 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; BLADDER CANCER; CANCER CELL; CANCER GROWTH; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; P16 GENE; PATHOGENESIS; TUMOR SUPPRESSOR GENE; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BLADDER TUMOR; GENE EXPRESSION REGULATION; GENETICS; MALE; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; PROMOTER REGION; TRANSITIONAL CELL CARCINOMA; TUMOR CELL LINE;

ANIMALS; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; PROMOTER REGIONS, GENETIC; UP-REGULATION; URINARY BLADDER NEOPLASMS;

EID: 84982263769     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.26624     Document Type: Erratum

References (33)

1. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S, Lotan Y. Epidemiology and risk factors of urothelial bladder cancer. European urology. 2013; 63:234-241.
2. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116:281-297.
3. Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T, Visakorpi T. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. European urology. 2011; 59:671-681.
4. Ventura A, Jacks T. MicroRNAs and cancer: short RNAs go a long way. Cell. 2009; 136:586-591.
5. Moretti F, Thermann R, Hentze MW. Mechanism of translational regulation by miR-2 from sites in the 5' untranslated region or the open reading frame. Rna. 2010; 16:2493-2502.
6. Qin W, Shi Y, Zhao B, Yao C, Jin L, Ma J, Jin Y. miR-24 regulates apoptosis by targeting the open reading frame (ORF) region of FAF1 in cancer cells. PloS one. 2010; 5:e9429.
7. Salmanidis M, Pillman K, Goodall G, Bracken C. Direct transcriptional regulation by nuclear microRNAs. The international journal of biochemistry & cell biology. 2014; 54:304-311.
8. Li LC, Okino ST, Zhao H, Pookot D, Place RF, Urakami S, Enokida H, Dahiya R. Small dsRNAs induce transcriptional activation in human cells. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103:17337-17342.
9. Liggett WH, Jr. and Sidransky D. Role of the p16 tumor suppressor gene in cancer. Journal of clinical oncology. 1998; 16:1197-1206.
10. Rayess H, Wang MB, Srivatsan ES. Cellular senescence and tumor suppressor gene p16. International journal of cancer Journal international du cancer. 2012; 130:1715-1725.
11. Rocco JW, Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Experimental cell research. 2001; 264:42-55.
12. Schaefer A, Jung M, Kristiansen G, Lein M, Schrader M, Miller K, Stephan C, Jung K. MicroRNAs and cancer: current state and future perspectives in urologic oncology. Urologic oncology. 2010; 28:4-13.
13. Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, Kawamoto K, Kawahara K, Toki K, Kawakami K, Nishiyama K, Tsujimoto G, Nakagawa M, Seki N. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. International journal of cancer. 2009; 125:345-352.
14. Yoshino H, Seki N, Itesako T, Chiyomaru T, Nakagawa M, Enokida H. Aberrant expression of microRNAs in bladder cancer. Nature reviews Urology. 2013; 10:396-404.
15. Fendler A, Stephan C, Yousef GM, Jung K. MicroRNAs as regulators of signal transduction in urological tumors. Clinical chemistry. 2011; 57:954-968.
16. Lai EC. Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation. Nature genetics. 2002; 30:363-364.
17. Place RF, Li LC, Pookot D, Noonan EJ, Dahiya R. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105:1608-1613.
18. Majid S, Dar AA, Saini S, Yamamura S, Hirata H, Tanaka Y, Deng G, Dahiya R. MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer. Cancer. 2010; 116:5637-5649.
19. Wang C, Chen Z, Ge Q, Hu J, Li F, Hu J, Xu H, Ye Z, Li LC. Up-regulation of p21(WAF1/CIP1) by miRNAs and its implications in bladder cancer cells. FEBS letters. 2014; 588:4654-4664.
20. Portnoy V, Huang V, Place RF, Li LC. Small RNA and transcriptional upregulation. Wiley interdisciplinary reviews RNA. 2011; 2:748-760.
21. Morris KV, Chan SW, Jacobsen SE, Looney DJ. Small interfering RNA-induced transcriptional gene silencing in human cells. Science. 2004; 305:1289-1292.
22. Matzke M, Aufsatz W, Kanno T, Daxinger L, Papp I, Mette MF, Matzke AJ. Genetic analysis of RNA-mediated transcriptional gene silencing. Biochimica et biophysica acta. 2004; 1677:129-141.
23. Ting AH, Schuebel KE, Herman JG, Baylin SB. Short double-stranded RNA induces transcriptional gene silencing in human cancer cells in the absence of DNA methylation. Nature genetics. 2005; 37:906-910.
24. Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochimica et biophysica acta. 2002; 1602:73-87.
25. Schulz P, Scholz A, Rexin A, Hauff P, Schirner M, Wiedenmann B, Detjen K. Inducible re-expression of p16 in an orthotopic mouse model of pancreatic cancer inhibits lymphangiogenesis and lymphatic metastasis. British journal of cancer. 2008; 99:110-117.
26. Tam KW, Zhang W, Soh J, Stastny V, Chen M, Sun H, Thu K, Rios JJ, Yang C, Marconett CN, Selamat SA, Laird-Offringa IA, Taguchi A, et al. CDKN2A/p16 inactivation mechanisms and their relationship to smoke exposure and molecular features in non-small-cell lung cancer. Journal of thoracic oncology. 2013; 8:1378-1388.
27. Wang GL, Lo KW, Tsang KS, Chung NY, Tsang YS, Cheung ST, Lee JC, Huang DP. Inhibiting tumorigenic potential by restoration of p16 in nasopharyngeal carcinoma. British journal of cancer. 1999; 81:1122-1126.
28. Lu Y, Zhang X, Zhang J. Inhibition of Breast Tumor Cell Growth by Ectopic Expression of p16/INK4A Via Combined Effects of Cell Cycle Arrest, Senescence and Apoptotic Induction, and Angiogenesis Inhibition. Journal of Cancer. 2012; 3:333-344.
29. Mitchell S Steiner YW, Yu Zhang, Xiongwen Zhang, Yi Lu. p16/MTS1/INK4A suppresses prostate cancer by both pRb dependent and independent pathways. Oncogene. 2000; 19:1297-1306.
30. Irene Orlow LL, Gregory J. Hannon, Manuel Serrano, Inmaculada Pellicer, Guido Dalbagni, Victor E. Renter, Zuo-Feng Zhang, David Beach, Carlos Cordon-Cardo. Deletion of the p16 and p15 Genes in Human Bladder Tumors. Journal of the National Cancer Institute. 1995; 87:1524-1529.
31. Magali P.Williamson PAE, Margaret E.Shaw, Jayne Devlin, Margaret A.Knowles. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Human Molecular Genetics. 1995; 4:1569-1577.
32. Abat D, Demirhan O, Inandiklioglu N, Tunc E, Erdogan S, Tastemir D, Uslu IN, Tansug Z. Genetic alterations of chromosomes, p53 and p16 genes in low-and high-grade bladder cancer. Oncology letters. 2014; 8:25-32.
33. Shimazui T, Yoshikawa K, Miyazaki J, Kojima T, Inai H, Ando S, Uemura H, Uchida K, Nishiyama H. Systemic transduction of p16INK4A antitumor peptide inhibits the growth of MBT-2 mouse bladder tumor cell line grafts. International journal of oncology. 2013; 42:543-548.